Celgene Corporation (NASDAQ:CELG):
2009 Third Quarter Financial Results Year-Over-Year:
- Non-GAAP Total Revenue Increased 18 Percent to $692 Million; GAAP Total Revenue $695 Million
- REVLIMID Net Product Sales Increased 31 Percent to $450 Million
- VIDAZA Net Product Sales Increased 62 Percent to $103 Million
- THALOMID® Net Product Sales Totaled $110 Million
- Non-GAAP Operating Income Increased 30 Percent to $292 Million; GAAP Operating Income $236 Million
- Non-GAAP Net Income Increased 40 Percent to $260 Million; GAAP Net Income $217 Million
- Non-GAAP Earnings Per Share Increased 40 Percent to $0.56 Per Diluted Share; GAAP Earnings $0.46 Per Diluted Share
Recent Developments And Highlights:
- REVLIMID® Reimbursement Approvals In United Kingdom And Canada
- Additional REVLIMID Regulatory Approvals in the Middle East and Latin America
- Lancet Oncology Published Results From ECOG EA403 Phase III Trial, Demonstrating REVLIMID Plus Low-Dose Dexamethasone Is An Active Regimen For Patients With Newly Diagnosed Multiple Myeloma (MM)
- NHL-001 Study Published In Journal Of Clinical Oncology Reported REVLIMID Demonstrated Single Agent Activity With Durable Responses In A Heavily Pretreated Patient Population
- Advancing REVLIMID Solid Tumor Program In Prostate Cancer, Renal Cell Carcinoma, Pancreatic Cancer, and Colorectal Cancer
- Journal Of Clinical Oncology Published Two Articles Highlighting Clinical Potential Of Pomalidomide As Treatment For MM and Myelofibrosis
- VIDAZA® Upgraded By National Comprehensive Cancer Network (NCCN) To Preferred Therapy Based On Unprecedented Survival For Intermediate-2 And High-Risk Myelodysplastic Syndromes (MDS)
- VIDAZA Now Listed By NCCN As Low Intensity Treatment Option For Patients With Acute Myeloid Leukemia
- Initiated Phase II Trial Of ACE-011 For Treatment Of Chemotherapy Induced Anemia In Metastatic Breast Cancer
- Completed Enrollment Of Phase I Proof-Of-Principle Study For Proprietary PDA-001 Placenta-Derived Stem Cells In Crohn’s Disease
- Celgene Cellular Therapeutics Patent Estate Highlighted In Nature Biotechnology
2009 Selected Corporate Objectives: